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MaBACKGROUND Obesity has been linked to the development of hypertension, but whether total adiposity or
site-speciﬁc fat accumulation underpins this relationship is unclear.
OBJECTIVES This study sought to determine the relationship between adipose tissue distribution and incident
hypertension.
METHODS Normotensive participants enrolled in the Dallas Heart Study were followed for a median of 7 years for the
development of hypertension (systolic blood pressure [SBP] $140 mm Hg, diastolic blood pressure $90 mm Hg, or
initiation of blood pressure medications). Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) was
quantiﬁed by magnetic resonance imaging and proton-spectroscopic imaging, and lower body fat (LBF) was imaged by
dual-energy x-ray absorptiometry. Multivariable relative risk regression was performed to test the association between
individual fat depots and incident hypertension, adjusting for age, sex, race/ethnicity, diabetes, smoking, SBP, and body
mass index (BMI).
RESULTS Among 903 participants (median age, 40 years; 57% women; 60% nonwhite; median BMI 27.5 kg/m2), 230
(25%) developed incident hypertension. In multivariable analyses, higher BMI was signiﬁcantly associated with incident
hypertension (relative risk: 1.24; 95% conﬁdence interval: 1.12 to 1.36, per 1-SD increase). However, when VAT, SAT, and
LBF were added to the model, only VAT remained independently associated with incident hypertension (relative risk:
1.22; 95% conﬁdence interval: 1.06 to 1.39, per 1-SD increase).
CONCLUSIONS Increased visceral adiposity, but not total or subcutaneous adiposity, was robustly associated with
incident hypertension. Additional studies will be needed to elucidate the mechanisms behind this association.
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998in other depots, such as visceral adipose tis-
sue (VAT), muscle, and liver. Whereas SAT is
relatively metabolically inert, VAT is associ-
ated with increased cytokine production (5)
and insulin resistance (4).SEE PAGE 1003The question remains whether the associ-
ation between obesity and hypertension is
inﬂuenced by site-speciﬁc adipose tissue
accumulation. We hypothesized that VAT
mass, rather than SAT or the degree of overall
adiposity, would be associated with the
development of hypertension.
METHODSSTUDY POPULATION. The DHS study (Dallas Heart
Study) is a multiethnic, probability-based cohort
study of Dallas County adults (age 18 to 65 years),
with deliberate oversampling of African-American
participants (6). The study schema is summarized
in Figure 1. The current study population was drawn
from 2,716 participants who completed all 3 visits of
DHS phase 1 (DHS-1) from 2000 to 2002, which
included blood pressure (BP) measurements, labo-
ratory testing, abdominal magnetic resonance imag-
ing (MRI), and dual-energy x-ray absorptiometry
(DEXA) scan. Of these participants, those withParticipants with 1 of the following
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ce imaging.baseline hypertension (systolic blood pressure
[SBP] $140 mm Hg, diastolic blood pressure
[DBP] $90 mm Hg, or on antihypertensive medica-
tions) were excluded, as were participants with
borderline BP elevations at baseline (SBP $130 or
DBP $85 mm Hg) to preclude minimal increases in
BP meeting the incident hypertension deﬁnition.
After these exclusions, 1,306 participants were
eligible for follow-up.
Of these, 903 participants completed all 3 visits of
DHS-1 and returned for DHS phase 2 (DHS-2), which
consisted of follow-up studies during a single visit
between 2007 and 2009. This comprised the current
study population. There were no signiﬁcant differ-
ences in medical history, demographics, or biomarker
data between eligible participants who did and did
not complete DHS-2 (4). All participants provided
written informed consent, and the University of
Texas-Southwestern Medical Center institutional
review board approved the protocol.
HYPERTENSION DEFINITION. Trained professionals
took BP measurements after 5 min of rest in the
seated position using an automated oscillometric
device (Series #52,000, Welch Allyn, Arden, North
Carolina). Five measurements were taken, and the
last 3 readings were averaged. Antihypertensive
medications were deﬁned as any diuretic, alpha-
blocker, beta-blocker, calcium channel blocker,
angiotensin-converting-enzyme inhibitor or angio-
tensin receptor blocker, nitrate, and hydralazine.
Participants were asked to bring all their medications
to their visit, and a trained professional examined all
of the medications thoroughly. In both phases of the
DHS, hypertension was deﬁned as SBP $140 mm Hg,
DBP $90 mm Hg, or the participant taking any anti-
hypertensive medications.
ABDOMINAL FAT QUANTIFICATION. Participants
were scanned at their baseline exam by a 1.5-T
MRI scanner (Intera, Philips Healthcare, Best, the
Netherlands). Retroperitoneal, intraperitoneal, and
SAT abdominal fat masses were quantiﬁed by a single
MRI slice taken at the L2–L3 level using manual con-
tours, as previously validated against cadaveric
samples (7). Areas were converted to mass (kg) using
previously determined regression equations (8). VAT
was then deﬁned as the combination of both retro-
peritoneal and intraperitoneal fat masses to express
the total intra-abdominal fat mass (4,9). Subjects
also underwent 1H-magnetic resonance spectroscopy
for hepatic triglyceride quantiﬁcation, as previously
described (10).
LOWER BODY FAT QUANTIFICATION. Participants
were scanned by DEXA, which was performed with a
TABLE 1 Demographic, Clinical, Imaging, and Biochemical Characteristics of
the Study Population at Baseline Examination
Entire Cohort
(N ¼ 903)
No Hypertension
(n ¼ 673)
Hypertension
(n ¼ 230) p Value
Age, yrs 40 (34, 47) 39 (33, 46) 43 (37, 49) <0.0001
Men 388 (43) 299 (44) 89 (39) 0.13
Black 349 (39) 221 (33) 128 (56) <0.0001
White 364 (40) 298 (44) 66 (29) <0.0001
Hispanic 172 (19) 137 (20) 35 (15) 0.09
Smoking 208 (23) 141 (21) 67 (29) 0.01
Prevalent DM 32 (4) 15 (2) 17 (7) 0.0003
Systolic BP, mm Hg 117 (109, 125) 114 (107, 122) 124 (117, 130) <0.0001
Diastolic BP, mm Hg 74 (69, 79) 72 (67, 77) 79 (75, 83) <0.0001
Cholesterol, mg/dl 175 (153, 202) 174 (152, 201) 180 (157, 204) 0.13
HDL, mg/dl 48 (40, 59) 48 (41, 59) 48 (40, 59) 0.66
Triglyceride, mg/dl 86 (62, 124) 84 (61, 121) 96 (64, 140) 0.02
LDL, mg/dl 104 (83, 125) 103 (82, 125) 109 (88, 125) 0.35
GFR, ml/min 98 (86,112) 97 (86,109) 100 (88,116) 0.02
HOMA-IR 2.2 (1.3, 3.9) 2.0 (1.2, 3.5) 3.3 (1.6, 5.2) <0.0001
BMI, kg/m2 27.5 (23.8, 32.0) 26.9 (23.3, 30.7) 29.9 (26.1, 36.5) <0.0001
VAT, kg 1.8 (1.2, 2.5) 1.7 (1.2, 2.4) 2.0 (1.5, 2.8) <0.0001
RP fat, kg 0.7 (0.5, 1.0) 0.6 (0.5, 0.9) 0.7 (0.6, 1.0) <0.0001
IP fat, kg 1.1 (0.7, 0.9) 1.0 (0.7, 1.5) 1.3 (0.9, 1.7) <0.0001
SAT, kg 3.7 (2.4, 5.5) 3.4 (2.4, 5.1) 4.8 (3.1, 7.1) <0.0001
LBF, kg 8.3 (5.9, 11.5) 7.9 (5.8, 10.8) 9.8 (6.9, 13.1) <0.0001
Liver fat, % 3.0 (1.9, 5.2) 2.8 (1.8, 4.7) 3.8 (2.6, 6.6) <0.0001
Cystatin C 0.79 (0.72, 0.88) 0.79 (0.71, 0.87) 0.81 (0.72, 0.91) 0.04
hs-CRP, mg/dl 1.9 (0.8, 4.7) 1.7 (0.7, 4.2) 2.6 (1.1, 7) 0.0001
Leptin, ng/l 9.9 (4.5, 22.8) 9.0 (3.9, 19.4) 16.7 (6.1, 30) <0.0001
Adiponectin, mg/ml 7.4 (4.8, 10.4) 7.8 (5.1, 10.7) 6.7 (4.4, 8.9) 0.0002
IL-6, pg/ml 16.5 (0, 34.5) 16.9 (0, 36.0) 15.0 (0, 29.4) 0.11
NT-proBNP, pg/ml 26.4 (12.7, 49) 26.8 (12.6, 49) 26.0 (13.1, 50) 0.87
Values are median (25th, 75th percentiles) or n (%).
BMI ¼ body mass index; BP ¼ blood pressure; DM ¼ diabetes mellitus; GFR ¼ glomerular ﬁltration rate; HDL ¼
high-density lipoprotein; hs-CRP ¼ high-sensitivity C-reactive protein; IL-6 ¼ interleukin-6; IP ¼ intraperitoneal;
LBF ¼ lower body fat; LDL ¼ low-density lipoprotein; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
RP ¼ retroperitoneal; SAT ¼ subcutaneous adipose tissue; VAT ¼ visceral adipose tissue.
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999Delphi W scanner (Hologic, Bedford, Massachusetts)
with a fan beam to determine fat and lean mass (11).
Lower body fat (LBF) was quantiﬁed from the total fat
mass from the lower extremities, and it was reported
in kilograms.
BIOMARKER ANALYSIS. Venous blood was collected
in tubes containing EDTA and was maintained at 4C
for <4 h. Plasma was then removed and frozen
at 80C until assays were performed. Samples were
analyzed for high-sensitivity C-reactive protein
(hs-CRP), interleukin (IL)-6, cystatin-C, N-terminal
pro–B-type natriuretic peptide (NT-pro-BNP), adipo-
nectin, leptin, fasting glucose, and insulin levels
(Online Appendix).
STATISTICAL ANALYSIS. Baseline demographic,
clinical, laboratory, and imaging variables are
expressed as median (25th, 75th percentile) or pro-
portions, as appropriate. Differences in variables
between normotensive participants and those with
incident hypertension were compared using chi-
square tests or the Wilcoxon rank sum test. Multi-
variable relative risk regression models with a log link
and binomial error distribution were created to
analyze associations between individual measures of
adiposity and incident hypertension while adjusting
for age, sex, race/ethnicity, history of smoking,
diabetes mellitus, and baseline SBP. Correlation co-
efﬁcients and variance inﬂation factors for adiposity
measures are shown in the Online Appendix. In-
teractions were also tested in the fully adjusted
model to assess for differential relationships between
body mass index (BMI)/VAT on incident hypertension
by sex, age, and race (black vs. non-black). Two-sided
p values <0.05 were considered signiﬁcant. All ana-
lyses were performed using SAS version 9.2 (SAS
Corporation, Cary, North Carolina).RESULTS
The study cohort consisted of 903 initially normo-
tensive (SBP <130 mm Hg and DBP <85 mm Hg)
participants. Their clinical characteristics are shown
in Table 1.
INCIDENT HYPERTENSION. After a median of 7 years
of follow-up, 230 participants (25%) developed
hypertension. As shown in Table 1, those who
developed hypertension were older, more commonly
black, had a higher prevalence of diabetes, and had
a higher baseline BP at the baseline examination
(p < 0.01 for each). They also had higher measures of
adiposity, including higher BMI, VAT (including
retroperitoneal and intraperitoneal fat), SAT, andLBF (Table 1). Although the baseline BMI was higher
among participants who developed hypertension
than those who did not (29.9 kg/m2 vs. 26.8 kg/m2,
p < 0.0001), the median interval weight increase
between groups was essentially identical (3.5 kg vs.
3.6 kg, p ¼ 0.70).
In multivariable risk regression models, increasing
BMI was signiﬁcantly associated with the develop-
ment of incident hypertension (Table 2). However,
when both VAT and SAT were added to the model,
increasing VAT was the only fat parameter indepen-
dently associated with incident hypertension (rela-
tive risk: 1.22 [95% conﬁdence interval 1.07 to 1.39]
per 1-SD increase in VAT; p ¼ 0.004), whereas BMI
and SAT were no longer signiﬁcant. LBF was not
associated with incident hypertension nor attenuated
the association of VAT with incident hypertension.
There was no difference noted in the relationship
TABLE 2 Results of the Multivariate Risk Regression of
Measures of Adiposity on Incident Hypertension
RR (95% CI) p Value
Model 1*
BMI 1.24 (1.12–1.36) <0.0001
Model 2*
BMI 1.14 (0.90–1.43) 0.27
VAT 1.22 (1.07–1.39) 0.003
SAT 0.97 (0.78–1.20) 0.78
Model 3*
BMI 1.16 (0.89–1.52) 0.27
VAT 1.22 (1.06–1.39) 0.004
SAT 0.95 (0.75–1.20) 0.66
LBF 1.01 (0.83–1.23) 0.91
Relative risk of developing hypertension per 1-SD increase in adiposity measure.
*Models adjusted for age, baseline systolic BP, sex, race/ethnicity, history of
smoking, and diabetes mellitus.
CI ¼ conﬁdence interval; RR ¼ relative risk; other abbreviations as in Table 1.
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1000between VAT and hypertension based on gender, age,
or race (interaction p value >0.1 for each).
The association between VAT and incident hyper-
tension remained signiﬁcant after further adjusting
for levels of inﬂammatory markers (hs-CRP, IL-6),
adipokines (adiponectin, leptin), insulin-resistance
(homeostatic model assessment of insulin resis-
tance), renal function (cystatin-C), or NT-proBNP
(Online Figure 1).
SUBDIVISION OF INTRA-ABDOMINAL FAT. The re-
sults of the multivariate model were qualitatively
similar when either liver fat or retroperitoneal fat, but
not intraperitoneal fat, were tested in place of VAT as
a marker of ectopic fat (Table 3). In quartile analysis,
there was a graded dose-response observed betweenTABLE 3 Results of the Multivariate Risk Regression of Speciﬁc
Measures of Intra-Abdominal Adiposity on Incident Hypertension
RR (95% CI) p Value
Model 1*
Liver fat 1.13 (1.02–1.25) 0.02
Model 2*
IP fat 1.09 (0.84–1.40) 0.51
Model 3*
RP fat 1.09 (1.05–1.13) <0.0001
Model 4*
IP fat (kg) 1.10 (0.98–1.23) 0.12
RP fat (kg) 1.12 (1.02–1.23) 0.02
Liver fat (%) 1.10 (0.99–1.22) 0.08
Relative risk of developing hypertension per 1-S.D. increase in adiposity measure.
*Models adjusted for age, baseline systolic BP, sex, race/ethnicity, history of
smoking, diabetes mellitus, BMI, SAT, and LBF.
Abbreviations as in Tables 1 and 2.retroperitoneal fat and the risk of developing hyper-
tension (Figure 2). This association was seen even
among those with the lowest quartile of baseline SAT
(Online Figure 2). After simultaneously adjusting for
each intra-abdominal fat depot, only retroperitoneal
fat was signiﬁcantly associated with incident hyper-
tension in the fully adjusted multivariable model
(Table 3).DISCUSSION
In this probability-based cohort study, among
individuals who were initially normotensive, a
greater amount of visceral adiposity was associated
with an increased risk for the development of
hypertension after a median of 7 years of follow-up
(Central Illustration). Addition of VAT to the multi-
variable model attenuated the association of BMI
with incident hypertension, suggesting that visceral
adipose, rather than total adiposity, is more impor-
tant in this relationship.
A prior study reported an association between VAT
and incident hypertension in a cohort of Japanese
Americans. Similar to our study, intra-abdominal fat
by computed tomography was independently associ-
ated with incident hypertension (9). Our study ex-
tends these observations and highlights the possible
speciﬁc pathological role of retroperitoneal fat.
There is growing evidence that VAT represents a
pathological adipose tissue depot, which accumulates
when subcutaneous depots are overwhelmed or
otherwise unavailable for storage. Relative to SAT,
visceral fat is more sensitive to lipolysis and secretesQuartile 1
Quartile 2
Quartile 3
Quartile 4
Quartile 1
Quartile 2
Quartile 3
Quartile 4
Unadjusted
Adjusted
0.1 1 10
Relative Risk Ratio
Referent group
Referent group
1.62 [1.07, 2.45]
1.48 [0.98, 2.22]
1.54 [1.02, 2.32]
1.84 [1.20, 2.84]
2.06 [1.39, 3.06]
2.92 [2.02, 4.23]
FIGURE 2 Incidence of Hypertension Increases With RP Fat
Forest plot of the graded risk for incident hypertension across
sex- and race-speciﬁc quartiles of retroperitoneal fat (RP), before
and after adjustment for clinical and demographic variables.
CENTRAL ILLUSTRATION Ectopic Fat Deposition Links Overnutrition With
Hypertension Development
Excess energy can either be stored in subcutaneous fat depots or in ectopic locations, such
as intrahepatic, periomental, or retroperitoneal. Such visceral fat depots, particularly
retroperitoneal, are speciﬁcally associated with incident hypertension.
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1001higher amounts of inﬂammatory cytokines (12). VAT is
associated with insulin resistance (3,13) and predicts
incident diabetes among obese adults (4). VAT is
associated with a higher atherosclerotic risk proﬁle
(14) and also recently has been prospectively linked
to adverse cardiovascular events (15). These results
suggest that VAT may be the important link between
BMI and cardiovascular disease, and that VAT may
be acting in part by promoting the development
of hypertension and insulin resistance (Central
Illustration).
The speciﬁc mechanisms behind the association of
VAT and hypertension are currently unknown, and it
remains a matter of considerable interest as to the
identity of the responsible drivers of hypertension in
this context. We did not note any signiﬁcant attenu-
ation of the relationship of VAT with hypertension
after adjusting for several biological pathways, sug-
gesting that this relationship might be independent of
these pathways.
Although our results from the speciﬁc intra-
abdominal fat depots should be regarded as
hypothesis-generating, it is nonetheless interesting
that the most signiﬁcant associations between
visceral adiposity and hypertension were observed
with retroperitoneal fat. To our knowledge, this
observation has not been reported previously, but if
validated, suggests that there may be local effects
from fat surrounding the kidneys that inﬂuence the
development of hypertension. Though this is a
small fat mass in relative terms, similar paracrine
effects have recently been suggested between
epicardial fat and the occurrence of coronary artery
disease (16,17).
In this study, we did not observe any protective
effect of LBF on the future development of hyper-
tension. This ﬁnding may suggest that LBF could
have a less important role in preventing hypertension
than it does in protecting against lipolysis and insulin
resistance (11).
STUDY LIMITATIONS. Although prospective, this is
still an observational study. Thus, we are unable to
draw a causal relationship between VAT and hyper-
tension. Approximately one-third of the eligible par-
ticipants from DHS-1 did not return for the second
phase of follow-up. Although we have previously not
observed any signiﬁcant clinical differences between
those who did and did not return for DHS-2 (4), this
remains a source of potential bias. Additionally, we
did not have available measures of site-speciﬁc
adiposity at follow-up, so we were unable to ac-
count for changes in adipose mass/distribution be-
tween examinations.CONCLUSIONS
These data from a multiethnic, probability-based
cohort demonstrate that the association between
obesity and the development of hypertension is spe-
ciﬁcally accounted for by visceral adiposity. The
strongest associations were observed with retroperi-
toneal fat. These data are consistent with a growing
body of literature implicating VAT, rather than
generalized adiposity, in the aggregation of cardio-
vascular risk factors that eventually drive adverse
clinical events.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Visceral
adiposity is closely associated with the development of
hypertension.
TRANSLATIONAL OUTLOOK: Identiﬁcation of the
paracrine mediators linking retroperitoneal fat to the
development of hypertension may open new avenues for
the prevention and management of hypertension.
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